Skip to main content
    P

    Phio Pharmaceuticals Corp (PHIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.93
    -0.02 (-2.51%)

    Market Cap: $11.03M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(24/33)
    Avg Surprise
    +3.31%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.36
    Range$-0.37 - $-0.35
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.33-10.8%
    60d ago$-0.33-10.8%
    30d ago$-0.35-2.9%
    7d ago$-0.360.0%
    Current$-0.36
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.49
    Range$-0.52 - $-0.47
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.49---
    Sep 26EST
    		-$-0.36---
    Jun 26
    Reported Aug 6
    		$-0.36$-0.36+0.00%Beat+20.0%
    Mar 26
    Reported May 7
    		$-0.34$-0.23-47.83%Miss+17.1%
    Dec 25
    Reported Mar 5
    		$-0.15N/A+68.09%Beat+82.4%
    Sep 25
    Reported Nov 13
    		$-0.44$-0.44+0.00%Beat+71.4%
    Jun 25
    Reported Aug 14
    		$-0.45$-0.36-25.00%Miss+87.6%
    Mar 25
    Reported May 15
    		$-0.41$0.00N/ABeat+73.2%
    Dec 24
    Reported Mar 31
    		$-0.85$-1.23+30.89%Beat+0.0%
    Sep 24
    Reported Nov 14
    		$-1.54N/A+62.80%Beat+85.0%
    Jun 24
    Reported Aug 14
    		$-3.62$-4.59+21.13%Beat-145.5%
    Mar 24
    Reported Apr 1
    		$-1.53N/A+86.92%Beat+51.5%
    Dec 23
    Reported Mar 20
    		$-0.85$-1.30+34.62%Beat+96.1%
    Sep 23
    Reported Nov 9
    		$-10.26$-12.87+20.28%Beat+63.5%
    Jun 23
    Reported Aug 10
    		$-1.47$0.00N/ABeat+92.8%
    Mar 23
    Reported May 11
    		$-3.15$0.00N/ABeat+84.6%
    Dec 22
    Reported Mar 22
    		$-21.78$-29.16+25.31%Beat-572.2%
    Sep 22
    Reported Nov 10
    		$-28.08$38.88-172.22%Miss+7.1%
    Jun 22
    Reported Aug 11
    		$-20.52$-33.48+38.71%Beat+5.0%
    Mar 22
    Reported May 12
    		$-20.52$-32.40+36.67%Beat-6312.5%
    Dec 21
    Reported Mar 22
    		$-3.24$-3.84+15.63%Beat+92.7%
    Sep 21
    Reported Nov 10
    		$-30.24$-27.00-12.00%Miss+30.0%
    Jun 21
    Reported Aug 12
    		$-21.60$-28.08+23.08%Beat+41.2%
    Mar 21
    Reported May 13
    		$-0.32$0.00N/ABeat+75.9%
    Dec 20
    Reported Mar 25
    		$-44.28$-45.36+2.38%Beat+91.8%
    Sep 20
    Reported Nov 10
    		$-43.20$-40.50-6.67%Miss+90.9%
    Jun 20
    Reported Aug 12
    		$-36.72$-69.66+47.29%Beat+92.3%
    Mar 20
    Reported May 12
    		$-1.33$0.00N/ABeat+99.8%
    Dec 19
    Reported Mar 26
    		$-543.24$-475.20-14.32%Miss-723.1%
    Sep 19
    Reported Nov 12
    		$-475.20$-475.20+0.00%Beat+76.5%
    Jun 19
    Reported Aug 12
    		$-475.20$-475.20+0.00%Beat+82.6%
    Mar 19
    Reported May 14
    		$-594.00$-475.20-25.00%Miss-1106.6%
    Dec 18
    Reported Mar 27
    		$-66.00$-72.60+9.09%Beat+98.7%
    Sep 18
    Reported Nov 14
    		$-2019.60$-2643.30+23.60%Beat+69.1%
    Jun 18
    Reported Aug 14
    		$-2732.40$-3504.61+22.03%Beat+57.6%
    Mar 18
    Reported May 10
    		$-49.23N/AN/ABeat+99.3%
    Dec 17
    Reported Mar 26
    		$-4989.61$-5702.41+12.50%Beat-26.0%
    Sep 17
    Reported Nov 8
    		$-6534.01$-6534.01+0.00%Beat-
    Jun 17
    Reported Aug 10
    		$-6444.91$-6534.01+1.36%Beat-
    Mar 17
    Reported May 11
    		$-7128.01$-6534.01-9.09%Miss-
    Dec 16
    Reported Mar 30
    		$-3960.00$-1518.00-160.87%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.72EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-113.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio8.39xQuick Ratio8.39x
    Trading Statistics
    Beta0.84Avg Volume104.17K
    52-Week High$2.1852-Week Low$0.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.97
    SMA 20$0.99
    SMA 50$1.05
    SMA 200$1.10
    EMA 10$0.96
    EMA 20$0.99
    EMA 50$1.02
    EMA 200$1.19

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 13.4+DI: 18.3-DI: 20.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down96.0
    PSAR$1.05

    Bollinger Bands

    Upper Band$1.06
    Lower Band$0.92
    %B Position1374%(Upper)
    Band Width0.02

    RSI (14-Day)

    Neutral
    34.4

    Momentum Oscillators

    Stoch %K17.7
    Stoch %D13.2
    Williams %R-84.4
    ROC (10d)-7.4%
    Momentum-0.07
    CCI (20d)-146.3
    MFI (14d)50.8

    Volatility Measures

    ATR (14d)$0.06(6.0%)
    StdDev (20d)0.03
    Hist Vol31.2%(Moderate)

    Volume Flow

    VWAP$0.94
    OBV74.8M
    AD Line-349.4M
    CMF (20d)-0.298

    Volume Metrics

    Avg Vol (20d)107.5K
    Vol Ratio1.3x
    VWMA (20d)$0.99

    Pivot Points

    R3$1.03
    R2$0.99
    R1$0.97
    Pivot Point$0.93
    S1$0.91
    S2$0.87
    S3$0.85

    Advanced Oscillators

    TSI-24.50
    Ultimate Osc38.0
    KST-87.30

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$70,000$0$0$0$6,000$0
    Cost of Revenue$0$0$1,000$0$0$0$35,000$0$0$0N/A$0
    Gross Profit$0$0$-1,000$0$0$0$35,000$0$0$0$6,000$0
    Operating Expenses$4.27M$4.17M$2.53M$2.50M$2.31M$1.87M$1.67M$1.59M$1.91M$2.21M$1.90M$2.78M
    R&D$3.08M$2.79M$1.48M$1.18M$1.07M$886,000$985,000$644,000$866,000$1.15M$1.01M$1.81M
    SG&A$1.19M$1.37M$1.06M$1.32M$1.24M$986,000$689,000$946,000$1.05M$1.06M$766,000$968,000
    Operating Income$-4,268,000$-4,167,000$-2,534,000$-2,505,000$-2,309,000$-1,872,000$-1,674,000$-1,590,000$-1,914,000$-2,209,000$-1,899,000$-2,776,000
    Interest Income$130,000$161,000$0$113,000$143,000$125,000$0$66,000$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$-53,000$2,000$4,000
    Income Before Tax$-4,138,000$-4,003,000$-2,393,000$-2,392,000$-2,166,000$-1,769,000$-1,626,000$-1,524,000$-1,846,000$-2,154,000$-1,901,000$-2,780,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-4,138,000$-4,003,000$-2,371,000$-2,392,000$-2,166,000$-1,769,000$-1,626,000$-1,524,000$-1,846,000$-2,154,000$-1,895,000$-2,780,000
    EBITDA$-4,267,000$-4,163,000$-2,533,000$-2,503,000$-2,309,000$-1,894,000$-1,738,000$-1,590,000$-1,845,000$-2,173,000$-1,856,000$-2,733,000
    EBIT$-4,268,000$-4,164,000$-2,534,000$-2,505,000$-2,309,000$-1,894,000$-1,738,000$-1,590,000$-1,846,000$-2,207,000$-1,899,000$-2,780,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHIO

    News

    Phio Pharmaceuticals Completes Commercial cGMP Batch of PH-762

    Phio Pharmaceuticals has successfully completed its first commercial-scale cGMP batch of PH-762 drug substance...

    The Clinical Trial Vanguard•10/14/26•Bullish

    Phio Pharmaceuticals completes first commercial-scale cGMP batch of PH-762, supporting Phase 2b start in Q1 2027

    Phio Pharmaceuticals has successfully completed the first commercial-scale cGMP batch of its PH-762 drug substance. This achievement supports the planned initiation of a Phase 2b study in Q1 2027 and demonstrates...

    TradingView•10/13/26•Bullish

    Phio Pharmaceuticals completes first commercial-scale cGMP batch of PH-762, supporting Phase 2b start in Q1 2027

    Phio Pharmaceuticals successfully completed its first commercial-scale cGMP batch of PH-762 drug substance, a crucial step for its planned Phase 2b clinical trial in Q1 2027. This milestone validates the manufacturing...

    TradingView•10/13/26•Bullish

    Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

    Phio Pharmaceuticals has successfully completed its first commercial-scale cGMP batch of PH-762 drug substance...

    Yahoo Finance•10/13/26•Bullish

    A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027.

    Phio Pharmaceuticals has successfully completed its first commercial-scale cGMP batch of PH-762 drug substance...

    Stock Titan•10/13/26•Bullish

    PHIO Valuation and Fair Value

    P/E
    -0.7x
    Forward P/E
    0.3x
    P/B
    0.9x
    See GNG's fair value

    PHIO Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -113.7%

    PHIO Competitors

    CompanyTicker
    Ensysce Biosciences IncENSC
    Cytosorbents CrpCTSO
    Kiora Pharmaceuticals IncKPRX
    NLS Pharmaceutics AGNLSP
    Alaunos Therapeutics IncTCRT
    CytoMed Therapeutics Limited Ordinary SharesGDTC
    Tempest Therapeutics IncTPST
    Biovie IncBIVI

    Sector: Healthcare

    PHIO Bull Case vs Bear Case

    Bear case

    • PHIO beat EPS estimates in 37.5% of its last 8 reported quarters.

    PHIO Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    12.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.36
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About PHIO

    Does PHIO pay dividends?

    Phio Pharmaceuticals Corp (PHIO) does not currently pay a regular dividend.

    What is PHIO's market cap?

    Phio Pharmaceuticals Corp (PHIO) has a market capitalization of $11.03M with a current stock price of $0.93.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In